Dr. Reddy’s Laboratories Ltd (NYSE:RDY) Receives Average Rating of “Moderate Buy” from Analysts

by · The Cerbat Gem

Dr. Reddy’s Laboratories Ltd (NYSE:RDY – Get Free Report) has received an average rating of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $16.90.

RDY has been the topic of a number of recent research reports. Zacks Research upgraded shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Dr. Reddy’s Laboratories in a research note on Wednesday, October 8th.

Check Out Our Latest Stock Analysis on RDY

Institutional Trading of Dr. Reddy’s Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of RDY. LPL Financial LLC boosted its position in Dr. Reddy’s Laboratories by 10.0% during the first quarter. LPL Financial LLC now owns 140,918 shares of the company’s stock valued at $1,859,000 after purchasing an additional 12,792 shares during the last quarter. Thornburg Investment Management Inc. raised its stake in shares of Dr. Reddy’s Laboratories by 1.8% during the 1st quarter. Thornburg Investment Management Inc. now owns 71,001 shares of the company’s stock worth $937,000 after purchasing an additional 1,250 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Dr. Reddy’s Laboratories by 2.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 39,743 shares of the company’s stock valued at $524,000 after buying an additional 1,099 shares during the last quarter. Costello Asset Management INC bought a new position in shares of Dr. Reddy’s Laboratories in the first quarter valued at $26,000. Finally, Vanguard Group Inc. increased its holdings in Dr. Reddy’s Laboratories by 2.2% during the first quarter. Vanguard Group Inc. now owns 5,002,642 shares of the company’s stock worth $65,985,000 after buying an additional 106,457 shares during the last quarter. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

Shares of Dr. Reddy’s Laboratories stock opened at $14.12 on Thursday. The firm has a market cap of $11.79 billion, a price-to-earnings ratio of 17.43, a price-to-earnings-growth ratio of 6.59 and a beta of 0.39. The stock’s 50-day moving average is $14.02 and its 200-day moving average is $14.43. Dr. Reddy’s Laboratories has a one year low of $12.26 and a one year high of $16.17. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.85 and a quick ratio of 1.35.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last posted its quarterly earnings data on Friday, October 24th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.13% and a net margin of 17.14%.The business had revenue of $993.72 million during the quarter, compared to the consensus estimate of $944.26 million. Equities analysts predict that Dr. Reddy’s Laboratories will post 0.8 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Company Profile

(Get Free Report)

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

Read More